Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET Â | Source: Cerevance, Inc. Phase 2 results…
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinsons Disease
December 05, 2025 08:00 ET Â | Source: Amneal Pharmaceuticals LLC Interim data…
A Mother’s Gift of Life: Successful Living-Donor Kidney Transplant Restores Hope for 32 Years old Young CKD Patient from Bangladesh
HYDERABAD, India, Nov. 24, 2025 /PRNewswire/ -- In an inspiring story of…
Eisai Submits New Drug Application for Subcutaneous Formulation of LEQEMBI for the Treatment of Early Alzheimers Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in…
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Antibody levels remained well above baseline across all six serotypes and age…
Alzheimer’s Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov.…
Clarivate Companies to Watch Report Spotlights Seven Women’s Health Startups Shaping the Future of Care
Report highlights emerging biotech innovators advancing new therapies, equity and investment across…
SMT Celebrates 20 Years of the Cocoon Occluder Journey, Transforming Lives in Congenital and Structural Heart Defects
Congenital Heart Disease (CHD) is one of the most common birth defects,…
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting 2025
Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in…